Novartis reports Q1 core EPS grew 23% in constant currency to $1.80

Reports Q1 revenue $11.83B, up 11% in cc, up 10% in U.S. dollars. Commenting on Q1 results, Vas Narasimhan, CEO of Novartis, said: “Novartis continued our strong momentum with both sales growth and core margin expansion in Q1. Our performance was broad-based, across all key growth brands and geographies, allowing us to raise guidance for the full year 2024. We continued to advance our pipeline in Q1, with submission-enabling data for Scemblix first-line, Pluvicto pre-taxane and remibrutinib in CSU. The momentum in our business and pipeline gives us continued confidence in our mid- and long-term growth outlook.”